Cargando…

Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab

Immunoglobulin E and its interactions with receptors FcϵRI and CD23 play a central role in allergic disease. Omalizumab, a clinically approved therapeutic antibody, inhibits the interaction between IgE and FcϵRI, preventing mast cell and basophil activation, and blocks IgE binding to CD23 on B cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Anna M., Allan, Elizabeth G., Keeble, Anthony H., Delgado, Jean, Cossins, Benjamin P., Mitropoulou, Alkistis N., Pang, Marie O. Y., Ceska, Tom, Beavil, Andrew J., Craggs, Graham, Westwood, Marta, Henry, Alistair J., McDonnell, James M., Sutton, Brian J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2017
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473249/ https://www.ncbi.nlm.nih.gov/pubmed/28438838 http://dx.doi.org/10.1074/jbc.M117.776476

Ejemplares similares

Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization
por: Mitropoulou, Alkistis N., et al.
Publicado: (2020)

Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody
por: Chen, Jiun-Bo, et al.
Publicado: (2018)

Mapping of the CD23 Binding Site on Immunoglobulin E (IgE) and Allosteric Control of the IgE-FcϵRI Interaction
por: Borthakur, Susmita, et al.
Publicado: (2012)

IgE binds asymmetrically to its B cell receptor CD23
por: Dhaliwal, Balvinder, et al.
Publicado: (2017)

IgE Trimers Drive SPE-7 Cytokinergic Activity
por: Bax, Heather J., et al.
Publicado: (2017)

Conformational plasticity at the IgE-binding site of the B-cell receptor CD23()
por: Dhaliwal, Balvinder, et al.
Publicado: (2013)

Inhibition of IgE and IgE/anti-IgE mediated responses in mast cells by Omalizumab
por: Kulka, M, et al.
Publicado: (2010)

Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
por: Pennington, Luke F., et al.
Publicado: (2016)

Inhibition of allergen‐dependent IgE activity by antibodies of the same specificity but different class
por: Dodev, T. S., et al.
Publicado: (2015)

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells
por: Chan, Marcia A, et al.
Publicado: (2013)

The structure of human CD23 and its interactions with IgE and CD21
por: Hibbert, Richard G., et al.
Publicado: (2005)

Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE
por: R, Divya, et al.
Publicado: (2020)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy
por: Kariyawasam, Harsha H, et al.
Publicado: (2020)

IgG and IgE Autoantibodies to IgE Receptors in Chronic Spontaneous Urticaria and Their Role in the Response to Omalizumab
por: Maronese, Carlo Alberto, et al.
Publicado: (2023)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

Current and future applications of the anti-IgE antibody omalizumab
por: Incorvaia, Cristoforo, et al.
Publicado: (2008)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
por: Tajiri, Tomoko, et al.
Publicado: (2023)

Crystal structures of the human IgD Fab reveal insights into C(H)1 domain diversity
por: Davies, Anna M., et al.
Publicado: (2023)

A range of C∊3–C∊4 interdomain angles in IgE Fc accommodate binding to its receptor CD23
por: Dhaliwal, Balvinder, et al.
Publicado: (2014)

A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma
por: D’Amato, Gennaro, et al.
Publicado: (2007)

Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels—A pilot study
por: Eckl‐Dorna, J., et al.
Publicado: (2017)

Human immunoglobulin E flexes between acutely bent and extended conformations
por: Drinkwater, Nyssa, et al.
Publicado: (2014)

Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
por: Humbert, Marc, et al.
Publicado: (2013)

Serum free IgE guided dose reduction of omalizumab: a case report
por: Gon, Yasuhiro, et al.
Publicado: (2017)

Structure of a patient-derived antibody in complex with allergen reveals simultaneous conventional and superantigen-like recognition
por: Mitropoulou, Alkistis N., et al.
Publicado: (2018)

Cytokinergic IgE Action in Mast Cell Activation
por: Bax, Heather J., et al.
Publicado: (2012)

Ontogeny of human IgE‐expressing B cells and plasma cells
por: Ramadani, F., et al.
Publicado: (2016)

Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review
por: D’Amato, Gennaro, et al.
Publicado: (2014)

Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2019)

The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
por: Gasser, Pascal, et al.
Publicado: (2020)

IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies
por: Barrios, D. M., et al.
Publicado: (2021)

Generation and Characterization of Native and Sialic Acid-Deficient IgE
por: McCraw, Alex J., et al.
Publicado: (2022)

IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms
por: Kuo, Be-Sheng, et al.
Publicado: (2022)

Serum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by Omalizumab
por: Roth, Michael, et al.
Publicado: (2015)

Levofloxacin Induced Toxic Epidermal Necrolysis: Successful Therapy with Omalizumab (Anti-IgE) and Pulse Prednisolone
por: Uzun, Rusen, et al.
Publicado: (2016)

The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Omalizumab for STAT3 Hyper-IgE Syndromes in Adulthood: A Case Report and Literature Review
por: Lan, Jun, et al.
Publicado: (2022)

IgE Antibodies: From Structure to Function and Clinical Translation
por: Sutton, Brian J., et al.
Publicado: (2019)

Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab
por: Saavedra, Michael C, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_dqval0mbu32glunl0dobo8bjb6